Plain-English translation of NCT06954584 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called fluzoparib to see if it works better when combined with other treatments after chemotherapy for advanced ovarian cancer. The study will compare the medication given alone versus combined with either an infused antibody drug () or a dietary intervention, depending on whether your cancer cells have a specific genetic feature called HRD.
Previous research suggests that combining this medication with other approaches may help kill cancer cells more effectively and improve how long patients survive. This trial will test whether these combinations truly offer better results than the medication alone.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of several treatment groups based on your cancer's HRD status. If your cancer has HRD, you'll take the medication by mouth twice daily and either receive an infusion of every 3 weeks or continue with the medication alone. If your cancer does not have HRD, you'll take the medication twice daily and either follow a low-carbohydrate diet or take the medication alone. Treatment continues until your cancer progresses or side effects become too severe, with follow-up visits and blood tests to monitor your health and response.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China